Bluebird Bio taps ex-Celgene exec Heffron to lead its first gene therapy launch

15th January 2020 Uncategorised 0

After a manufacturing delay, Bluebird Bio has officially launched Zynteglo, its first gene therapy. And Nicola Heffron, a former Celgene exec, is tasked with charting the commercial course in Europe, its first proving ground, while the company works toward approval in the U.S.

More: Bluebird Bio taps ex-Celgene exec Heffron to lead its first gene therapy launch
Source: fierce